WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Pro Bono
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
DOJ Takes Down $1.2 Billion Healthcare Fraud Scheme
Alerts
April 12, 2019

On April 9, 2019, the Department of Justice (DOJ), working with multiple departments and agencies, including the U.S. Department of Health and Human Services—Office of the Inspector General (HHS-OIG), brought enforcement actions against 24 defendants that included executives and business owners of telemedicine and durable medical equipment (DME) companies, and three licensed medical professionals, for their alleged participation in one of the largest healthcare fraud schemes ever targeted.1 Enforcement officials stated that more than $1.2 billion in losses to federal healthcare programs and patients resulted from an international web of fraud involving illegal kickbacks, bribes, and money-laundering. The DOJ named five companies connected to the scheme: Video Doctor USA, AffordADoc, Web Doctors Plus, Integrated Support Plus, and First Care MD. The Centers for Medicare and Medicaid Services (CMS) – Center for Program Integrity (CMS-CPI) also brought adverse administrative actions against 130 DME companies that billed more than $1.7 billion in claims, of which more than $900 million was paid out.

According to the DOJ, the complex, multi-layered scheme involved a network of telemarketing call centers located in the Philippines and Latin America that advertised to and “upsold” elderly and/or disabled Medicare beneficiaries in the United States, pushing “free or low-cost” medical braces regardless of medical necessity. The call centers paid kickbacks and bribes to telemedicine companies, which in turn paid doctors to write orders for DME products with little or no interaction with the patients. Some doctors reportedly spoke briefly by telephone with patients they never met or saw. The call centers then sold the orders to DME companies, which fraudulently billed Medicare. The defendants and their associates later laundered proceeds through international shell companies to buy exotic cars, yachts, and luxury property around the world, officials alleged.

This is not the first telemedicine fraud scheme taken down by the DOJ in recent years. In October 2018, four Florida men and seven pharmacies were indicted for a $1 billion fraud scheme that involved telemedicine.2Defendants set up a telemedicine company, HealthRight LLC, which allegedly deceived consumers and doctors at the center of a broad web of fraud. HealthRight LLC reached out to consumers across the country, fraudulently obtaining their insurance coverage information and pushing prescriptions for pain creams and other products. The company then contacted doctors, misrepresenting this consumer outreach as legitimate telemedicine consults. Doctors approved the prescriptions, which were then billed to insurance companies at prices steeply marked up by the defendants.

Given the rapid growth of telemedicine and digital health technologies in recent years, prosecutors and regulators are ramping up scrutiny. Companies that interact with or contract with healthcare professionals and/or manufacture or distribute products or services that are payable by Medicare, Medicaid, or other federal healthcare programs, should assess their compliance risks under five key federal fraud and abuse laws: the False Claims Act, the Anti-Kickback Statute, the Physician Self-Referral Law, the Exclusion Authorities, and the Civil Monetary Penalties Law.

For questions about healthcare laws, regulatory compliance, or FDA regulation and compliance, please contact David Hoffmeister, Georgia Ravitz, or any member of Wilson Sonsini's FDA/life sciences practice.

Eva Yin contributed to the preparation of this Wilson Sonsini alert.

 


1 DOJ, Press Release (April 9, 2019), available at https://www.justice.gov/opa/pr/federal-indictments-and-law-enforcement-actions-one-largest-health-care-fraud-schemes. 
2 DOJ, Press Release (October 15, 2018), available at https://www.justice.gov/opa/pr/four-men-and-seven-companies-indicted-billion-dollar-telemedicine-fraud-conspiracy.

Contributors

  • David M. Hoffmeister
  • Eva F. Yin
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.